You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Thermo will develop a test using its Oncomine Precision Assay to identify IDH1- and IDH2-positive low-grade glioma patients for treatment with Agios' vorasidenib.
The researchers believe using cerebral spinal fluid will enable them to identify brain tumors with a higher sensitivity than with blood samples.
The researchers aim to offer the half-hour diagnostic assay for use during neurosurgery to help clinicians pursue the best treatment for patients with gliomas.
This drug is the first FDA-approved IDH1 inhibitor and will be used to treat adult patients with relapsed or refractory acute myeloid leukemia.
The companies will work together on a next-generation sequencing-based companion diagnostic for Agios' investigational cancer drug ivosidenib.
The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.
Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.
Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.
In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.